Immutep (IMMP.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov14

Immutep Ltd. Announces Positive Phase II Trial Results for Eftilagimod Alfa in Soft Tissue Sarcoma

11:07

Oct29

Immutep Ltd. Shows Progress in LAG-3 Immunotherapy

06:49

Sep26

Analyst Storey Covers Healthcare Sector With Focus On Immutep Ltd

05:06

Aug29

Immutep released FY2025 Q4 earnings on August 28 (EST), actual revenue USD 618.59 K, actual EPS USD -0.0873

03:00

Immutep released FY2025 Q3 earnings on August 28 (EST), actual revenue USD 596.03K, actual EPS USD -0.0841

03:00

Immutep released FY2025 Annual Earnings on August 28 (EST), actual revenue USD 3.27 M (forecast USD 3.016 M), actual EPS USD -0.2735 (forecast USD -0.2392)

03:00

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 618.59 K, Net Income -12.74 M, EPS -0.0873

Feb26

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 979.06 K, Net Income -6.96 M, EPS -0.0479

Aug29

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 577.35 K, Net Income -7.167 M, EPS -0.059

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change